» Articles » PMID: 38555071

Common and Disparate Clinical Presentations and Mechanisms in Different Eosinophilic Gastrointestinal Diseases

Overview
Date 2024 Mar 30
PMID 38555071
Authors
Affiliations
Soon will be listed here.
Abstract

Eosinophilic gastrointestinal diseases (EGIDs) are a group of diseases characterized by selective eosinophil infiltration of the gastrointestinal (GI) tract in the absence of other causes of eosinophilia. These diseases are generally driven by type 2 inflammation, often in response to food allergen exposure. Among all EGIDs, the clinical presentation often includes a history of atopic disease with a variety of GI symptoms. EGIDs are traditionally separated into eosinophilic esophagitis (EoE) and non-EoE EGIDs. EoE is relatively better understood and now associated with clinical guidelines and 2 US Food and Drug Administration-approved treatments, whereas non-EoE EGIDs are rarer and less well-understood diseases without US Food and Drug Administration-approved treatments. Non-EoE EGIDs are further subclassified by the area of the GI tract that is involved; they comprise eosinophilic gastritis, eosinophilic enteritis (including eosinophilic duodenitis), and eosinophilic colitis. As with other GI disorders, the disease presentations and mechanisms differ depending on the involved segment of the GI tract; however, the differences between EoE and non-EoE EGIDs extend beyond which GI tract segment is involved. The aim of this article is to summarize the commonalities and differences between the clinical presentations and disease mechanisms for EoE and non-EoE EGIDs.

Citing Articles

A multicenter, retrospective cohort study on the diagnosis, treatment and natural history of eosinophilic gastrointestinal disorders in the Netherlands.

Gupta M, Haasnoot M, Mookhoek A, Bredenoord A Sci Rep. 2025; 15(1):7338.

PMID: 40025110 PMC: 11873234. DOI: 10.1038/s41598-025-91958-1.


Advances in omics data for eosinophilic esophagitis: moving towards multi-omics analyses.

Matsuyama K, Yamada S, Sato H, Zhan J, Shoda T J Gastroenterol. 2024; 59(11):963-978.

PMID: 39297956 PMC: 11496339. DOI: 10.1007/s00535-024-02151-6.

References
1.
Morgan D, Ruiter B, Smith N, Tu A, Monian B, Stone B . Clonally expanded, GPR15-expressing pathogenic effector T2 cells are associated with eosinophilic esophagitis. Sci Immunol. 2021; 6(62). PMC: 8686696. DOI: 10.1126/sciimmunol.abi5586. View

2.
Eliakim R, Carter D . Endoscopic assessment of the small bowel. Dig Dis. 2013; 31(2):194-8. DOI: 10.1159/000353367. View

3.
Philpott H, Nandurkar S, Royce S, Thien F, Gibson P . Allergy tests do not predict food triggers in adult patients with eosinophilic oesophagitis. A comprehensive prospective study using five modalities. Aliment Pharmacol Ther. 2016; 44(3):223-33. DOI: 10.1111/apt.13676. View

4.
Wright B, Doyle A, Shim K, Pai R, Barshow S, Horsley-Silva J . Image Analysis of Eosinophil Peroxidase Immunohistochemistry for Diagnosis of Eosinophilic Esophagitis. Dig Dis Sci. 2020; 66(3):775-783. PMC: 7541435. DOI: 10.1007/s10620-020-06230-5. View

5.
Rothenberg M . Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol. 2004; 113(1):11-28. DOI: 10.1016/j.jaci.2003.10.047. View